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Abstract
A therapeutic vaccine for individuals infected with HIV-1 and treated with antiretroviral therapy (ART) should be able to replenish
virus-specific CD4 T-cells and broaden the virus-specific CD8 T-cell response in order to maintain CD8 T-cell function and minimize viral
immune escape after ART cessation. Because a combination of DNA and recombinant poxvirus vaccine modalities induces high levels of
virus-specific CD4 T-cell response and broadens the cytolytic activity in naive macaques, we investigated whether the same results could be
obtained in SIVmac251-infected macaques. The macaques studied here were long-term nonprogressors that naturally contained viremia but were
nevertheless treated with a combination of antiviral drugs to assess more carefully the effect of vaccination in the context of ART. The combination
of a DNA expressing the gag and pol genes (DNA-SIV-gp) of SIVmac239 followed by a recombinant fowlpox expressing the same SIVmac genes
(FP-SIV-gp) was significantly more immunogenic than two immunizations of FP-SIV-gp in SIVmac251-infected macaques treated with ART. The
DNA/FP combination significantly expanded and broadened Gag-specific T-cell responses measured by tetramer staining, ELISPOT, and
intracellular cytokine staining and measurement of ex vivo cytolytic function. Importantly, the combination of these vaccine modalities also
induced a sizeable expansion in most macaques of Gag-specific CD8-(CD4) T-cells able to produce TNF-. Hopefully, this modality of vaccine
combination may be useful in the clinical management of HIV-1-infected individuals.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Although potent highly active antiretroviral therapy
(HAART) has decreased the mortality in HIV-1-infected
individuals (Palella, Jr. et al., 1998), the continuous sup-
pression of HIV-1 replication has been associated with
reconstitution of immune response to other pathogens but
not to HIV-1 (Autran et al., 1997). In fact, prolonged
HAART is associated with life-threatening toxicity and de-
creases virus-specific immune responses (Gray et al., 1999;
Ogg et al., 1999; Pitcher et al., 1999). Alternative ap-
proaches such as structured therapy interruption (STI) of
HAART have been attempted in the clinical management of
HIV-1 infection (Lori and Lisziewicz, 2001) with the dual
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purpose of decreasing drug toxicity and increasing virus-
specific responses through autovaccination (viral rebound
after STI). However, although STI is associated with an
increase in virus-specific immune responses, the long-term
benefit of STI in patients with long-standing HIV-1 infec-
tion is uncertain (Davey, Jr. et al., 1999; Ortiz et al., 1999).
The quality and/or quantity of the HIV-1-specific immune
response increased by viral rebound may not be sufficient to
maintain immune control of viral replication in the absence
of HAART. The importance of both virus-specific CD8
and CD4 T-cell responses have been demonstrated in
primary HIV-1 infection (Koup et al., 1994; Rosenberg et
al., 1997) as well as in patients infected with HIV-1 who
maintain stable CD4 T-cells and control viremia in the
absence of HAART (Pitcher et al., 1999; Rosenberg et al.,
2000). In the SIVmac macaque model of HIV-1 infection of
humans, the importance of CD8 T-cells has been demon-
strated indirectly by depletion studies (Jin et al., 1999;
Matano et al., 1998; Schmitz et al., 2000). In the same
model, the relevance of virus-specific CD4 T-cells has
been inferred by the finding of an inverse correlation be-
tween virus plasma level and the size of CD4 T-helper
responses in infected macaques (Hel et al., 2000, 2002a,
2002b; Tryniszewska et al., 2002) as well as by the fact that
adoptive transfer of autologous naive CD4 T-cells ame-
liorates control of viral replication (Villinger et al., 2002).
Thus, it is logical to infer that increasing the virus-
specific CD4 and CD8 T-cell response and perhaps
even more importantly the virus-specific CD4 T-cells may
be necessary to spare ART treatment of HIV-1-infected
individuals. The loss of CD4 T-lymphocytes in long-
standing HIV-1/SIV infection coupled with defects in the
number and/or function of virus-specific CD4 (Musey et
al., 1999; Rosenberg et al., 1997) and CD8 T-cells (Appay
et al., 2000; Goepfert et al., 2000; Hel et al., 2001a; Shankar
et al., 2000; Vogel et al., 2001) represents, however, serious
limitations for immune intervention. Therefore, immune-
based strategies need to be able to replenish CD4 T-helper
responses and possibly broaden the immune responses to
subdominant epitopes recognized by CD8 T-cells.
For this purpose, several vaccine modalities need to be
assessed and compared for their relative immunogenicity in
HIV-1-infected individuals. Among the live vectors, thus
far, only a canarypox-based recombinant HIV-1 vaccine
(ALVAC-HIV-1) has been tested in a phase I trial in hu-
mans and has been demonstrated to be safe and immuno-
genic. Vaccination with ALVAC-HIV-1 of HAART-treated
patients resulted in an increase of virus-specific cellular
immune response, which in turn was associated, in a subset
of patients, with transient suppression of plasma virus level
(Jin et al., 2002; Markowitz et al., 2002).
In the SIVmac model to date, both the canarypox-based
SIV (ALVAC-SIV) and the NYVAC-based SIV vaccine
candidates have proven to be immunogenic in naive (Ben-
son et al., 1998; Hel et al., 2001a, 2001b; Pal et al., 2001)
as well as in infected macaques (Hel et al., 2000, 2002b;
Tryniszewska et al., 2002). Both the ALVAC-SIV-gag-pol-
env (gpe) and the NYVAC-SIV-gpe vaccine candidates are
able to induce equivalent levels of virus-specific CD4 and
CD8 T-cells in macaques treated with ART during pri-
mary infection (Hel et al., 2002b). However, in both those
studies the role of the vaccine-induced responses in viremia
containment remained elusive since early initiation of ART
alone was associated with viremia containment following
drug suspension. A similar finding was also reported in
other studies in the SIVmac model (Lifson et al., 2000; Lori
et al., 2000; Mori et al., 2000; Tsai et al., 1995) as well as
in HIV-1-infected individuals treated with ART alone dur-
ing primary infection (Markowitz et al., 1999; Rosenberg et
al., 2000). Encouragingly, however, in macaques with long-
standing infection following vaccination either with NY-
VAC-based SIV vaccines (Tryniszewska et al., 2002) or
with the ALVAC-SIV-gpe-based vaccine (our unpublished
results), viral plasma levels remained significantly lower in
the vaccinated than control macaques after cessation of
ART, suggesting that vaccination prior to ART suspension
may provide clinical and virological benefit. However, the
containment of viremia in these macaques was transient
(Tryniszewska et al., 2002), suggesting that more immuno-
genic regimens may be necessary to obtain protracted vire-
mia containment in the absence of ART.
In naive macaques, prior immunization with DNA
greatly enhanced the immunogenicity of a recombinant pox-
virus-based NYVAC-SIV-gpe vaccine (Hel et al., 2001b)
and resulted in viremia containment following SIVmac251
mucosal challenge (Hel et al., 2002a). Similarly, when DNA
was used to prime and recombinant fowlpox or modified
Ankara virus (MVA) to boost, a higher immune response
was obtained (Amara et al., 2001; Hanke et al., 1999; Kent
et al., 1998; Robinson et al., 1999). Prior vaccination with
DNA was demonstrated to broaden cytotoxic T-lymphocyte
(CTL) responses (Amara et al., 2001; Hel et al., 2001b) and,
importantly, to increase significantly virus-specific CD4
T-helper cells, which in turn inversely correlated with virus
plasma level in macaques vaccinated with the DNA/NY-
VAC immunization regimen (Hel et al., 2002a).
With the aim of improving the immunogenicity of vac-
cines in SIV-infected macaques, we designed immunization
regimens to directly compare the relative immunogenicity
of a DNA/poxvirus to a poxvirus/poxvirus immunization in
Mamu-A*01-positive, SIVmac251-infected rhesus ma-
caques. These macaques were able to contain naturally
viremia but were nevertheless treated with ART to further
minimize and to avoid fluctuation in viral replication that
might affect the immune response to vaccination. Immuni-
zation with a plasmid expressing the gag/pol genes of SIV-
mac239 (pcDNA-SIV-gp) and followed with a recombinant
fowlpox (FP) construct expressing the SIVmac251 gag/pol
genes (FP-SIV-gp) (Jenkins et al., 1991) was compared to a
regimen of two FP-SIV-gp immunizations.
Our purpose was to determine the relative ability of these
immunization regimens to induce/expand Mamu-A*01-re-
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stricted SIV-specific CD8 and CD4 T-helper cells and
the ability of these cells to produce cytokines and the ef-
fector function of virus-specific CD8 T-cells and to assess
in parallel the durability of the virus-specific immune re-
sponses generated by the two immunization regimens. Since
all these SIVmac251-infected macaques were able to con-
tain naturally viremia even in the absence of ART treatment
(long-term nonprogressors), there was no plan to evaluate
the relative efficacy of these vaccine regimens on viremia
containment following ART cessation.
Results
Vaccination with the DNA-SIV-gp and FP-SIV-gp
combination induced higher frequency of functional
Gag181-189 CM9-specific CD8 T-cells than the
FP-SIV-gp vaccination alone
The eight SIVmac251-infected rhesus macaques enrolled
for the study contained viremia in the absence of ART
(long-term slow progressors) and had normal CD4 T-cell
counts. The previous treatment of these macaques is sum-
marized in Table 1. Even though these macaques had un-
detectable viremia, they were treated with ART to minimize
possible fluctuation in viral replication that may not have
been measurable by the plasma RNA copy assay and to
assess more carefully the effect of vaccination in the context
of ART. Viremia remained below the detection limit during
the entire immunization period (data not shown). Macaques
were divided into two groups of four macaques each and
immunized with plasmid DNA (DNA-SIV-gp) encoding the
Gag and Pol SIV proteins and with 2  108 pfu of recom-
binant FP-SIV-gp encoding the same proteins 8 weeks later
(group A), whereas the remaining macaques (group B) re-
ceived two immunizations with FP-SIV-gp at the same dose
at the time indicated in Fig. 1.
Because all the macaques included in this study carried the
MHC I Mamu-A *01 molecule, Gag-specific CD8 T-cells
were quantitated at first in blood using the Gag181–189 CM9
Mamu-A *01 tetrameric complexes. Whereas a negligible
increase in this CD8 T-cell population was found follow-
ing inoculation with DNA-SIV-gp, in the animals of group
A, a significant increase in the frequency of tetramer-stain-
ing CD8 T-cells was observed in all macaques from group
B within a few weeks from immunization with the FP-SIV-
gp. This response reached peak values at week 2, up to
17.78 and 15.45% in animals 645 and 650, respectively
(Fig. 2A), and in most macaques remained higher than the
prevaccination level until the second vaccination. The sec-
ond immunization with FP-SIV-gp in the same group of
macaques (group B) did not result in greater expansion of
this Gag-specific CD8 T-cell response (Fig. 2A). Surpris-
ingly, however, a much greater increase in the Gag-specific
tetramer-staining population of CD8 T-cells was observed
in three of the four macaques of group A, which had been
previously immunized with DNA, reaching frequencies in
blood of 24.4, 45.1, and 38.2% of the total CD8 T-cells in
macaques 636, 649, and 680, respectively. These frequen-
cies remained higher than the level preceding immunization
in these three animals for as long as 5 months following the
last immunization (Fig. 2A).
Statistical analysis of the frequency of these responses in
macaques from both groups using the repeated measures
Table 1
CD4 T-cell counts at the time of vaccination
Group Animal Duration of
SIVmac251
infection
(months)
Prior vaccination CD3/CD4 T-cells/mm3
at first immunization
CD3/CD4 T-cells/mm3
at second immunization
A 636 42 NYVAC-SIV-gpe 1107 1093
649 42 NYVAC 1004 1311
680 31 NYVAC 1062 1251
682 31 NYVAC 1122 1145
B 645 42 NYVAC 609 963
650 42 NYVAC-SIV-gpe 1152 2506
681 31 NYVAC 1365 1755
706 31 NYVAC 1197 1235
Fig. 1. Study design. The macaques in each group were immunized twice
at the times indicated. ART was initiated 4 weeks before vaccination and
maintained during the entire experiment. pcDNASIVgp and FPSIVgp
recombinants contained the complete gag/pol genes from SIVmac239. All
macaques were Mamu-A*01-positive and their previous treatment is sum-
marized in Table 1.
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analysis of variance of the arc-sine tetramer-positive per-
centage indicated that prior DNA immunization contributed
significantly to the expansion of this response (compare the
first FP-SIV-gp administration in groups A and B, P 
0.018). The increase in this population of Gag-specific cells
induced by the combination of DNA/FP-SIV-gp was also
significantly greater than that obtained after the second
FP-SIV-gp immunization of group B macaques (P 
0.0074). Although both immunization regimens resulted in
the maintenance of a high frequency of Gag-specific CD8
T-cells for several weeks postimmunization, the blood lev-
els of these cells remained higher over time in macaques
from group A than from group B, suggesting that the DNA/
FP-SIV-gp combination may elicit/expand a higher number
of memory T-cells. Prior immunization of two of these
macaques, 636 in group A and 650 in group B, did not
apparently influence these results since the former had in-
termediate response and the latter did not differ from the
remaining macaques in group B.
Because binding of CD8 T-cells to the specific tet-
ramer does not necessarily correlate with their ability to
produce cytokines, we tested the ability of these cells to
produce IFN- by ELISPOT and TNF- by intracellular
cytokine staining. After in vitro stimulation with the Mamu-
A*01-restricted SIVmac251-specific Gag181–189 CM9 pep-
tide, IFN--secreting spot-forming cells (SFCs) were
counted and the average number per million assessed after
subtracting the number of cells producing IFN- counted in
Fig. 2 (continued)
Fig. 2. Functional virus-specific T-cell response to Gag181–189 CM9 epitope induced by vaccination. Results of animals of groups A and B are shown. (A)
The frequency of CD3 CD8 T-cells was determined by tetramer staining using the Gag181–189 CM9 peptide. (B, left) IFN- production was measured
after specific antigenic stimulation with Gag181–189 CM9 peptide in an ELISPOT assay; (right) TNF- production was determined by intracellular cytokine
staining assay following stimulation with Gag181–189 CM9 peptide. (C) TNF- production raw data at week 12. The percentage of CD69 TNF--secreting
cells is shown at the top right in each panel. Unstimulated control cells are shown at the left side of each group.
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the absence of stimulation (average value of medium alone
in our conditions is 25 SFC/106 cells). DNA immunization
did not increase significantly the number of IFN--produc-
ing cells above the preimmunization level in any of the
macaques in group A (Fig. 2B, left panels). The first im-
munization of group B macaques with FP-SIV-gp increased
the frequency of Gag181–189 CM9-specific SFCs in three of
the four macaques and this response was not boosted by the
second FP-SIV-gp immunization (Fig. 2B). However, a
remarkable boost in the number of IFN--producing cells
occurred in group A within a week postimmunization with
the FP-SIV-gp in three of the four macaques. Thus, the
IFN- responses to the Gag181–189 CM9 peptide mirrored
closely the results obtained with the Gag181–189 CM9
Mamu-A*01 tetrameric complex.
To further confirm these findings with an additional
independent assay, intracellular TNF- staining was per-
formed following in vitro stimulation with the Gag181–189
CM9-specific peptide over several weeks after the second
immunization. A high number of CD8 T-cells produc-
ing TNF- following peptide-specific stimulation was
found in the same three of four macaques from group A
that had a high level of blood tetramer-positive cells (Fig.
2B, upper right panel). In macaques from group B, the
response to the second vaccination was lower (Fig. 2B,
right lower panel, and Fig. 2C). Thus, independent assays
demonstrated that the vaccine-induced expansion of the
Gag-specific response was higher and longer lasting in
the macaques previously immunized with DNA (group
A) than in macaques immunized at first with FP-SIV-gp
(group B).
Functional response to subdominant epitopes induced by
vaccination
To assess whether the DNA/FP-SIV-gp vaccine mo-
dality combination could also potentiate the response to
subdominant epitopes, an overlapping peptide pool (15
amino acids overlapping 11 amino acids) encompassing
the entire Gag protein of SIV and the subdominant pep-
tide, QI9, was used in ELISPOT and intracellular cyto-
kine staining assays. Assays using overlapping Env pep-
tides were also performed as a control since the Env
protein was not included in the vaccine. An overall
higher number of cells producing IFN- was found fol-
lowing stimulation with the gag pool than with the
Gag181–189 CM9 peptide alone (compare Fig. 3A, left
panel, to Fig. 2B), suggesting that other Gag epitopes
were also recognized by the T-cells of the immunized
macaques. Similarly, the frequency of TNF--producing
cells following in vitro stimulation with the subdominant
Gag QI9 peptide was higher in macaques of group A
immunized with the combination of DNA and FP-SIV-gp
than in macaques of group B that received two FP-
SIV-gp vaccinations (Fig. 3A, right top panel, and Fig.
3B). No significant increase of ELISPOT response to the
Env overlapping peptides was observed, as expected
(data not shown). Thus, the combination of these vaccine
modalities increased not only dominant but also sub-
dominant Gag-specific CD8 T-cell responses.
Ex vivo cytolytic activity to dominant and subdominant
Mamu-A*01-restricted epitopes in the immunized macaques
Since all the assays performed above assessed the ability
of antigen-specific cells to produce cytokines but did not
directly demonstrate their cytolytic function, 51Cr release
assays were performed in parallel to the other immunolog-
ical assays during the immunization regimens (Fig. 4). In
animals of group A, ex vivo cytolytic T-cells specific for the
Gag181–189 CM9 or Gag QI9 epitope were not detected at 5
weeks following immunization with DNA. However, by 5
weeks after the second immunization with FP-SIV-gp
(week 13), ex vivo cytolytic activity with both specificities
was readily detected in the blood of most macaques (three
of four) in this group and a low level of this cytolytic
activity to the dominant Gag181–189 CM9 peptide persisted
over time (Fig. 4). In contrast, in macaques from group B
only, ex vivo cytolytic activity to the dominant Gag181–189
CM9 epitope was detected at 5 weeks from the first immu-
nization and 2 weeks after the second immunization (week
15).
All together, these results demonstrate that, although ex
vivo CTL activity could be induced by FP-SIV-gp immu-
nization alone, macaques that received DNA before the
FP-SIV-gp vaccine had a higher level of and more durable
ex vivo CTLs to the dominant Gag181–189 CM9 and also
exhibited ex vivo cytolytic activity to the subdominant Gag
QI9 epitope.
Virus-specific CD4 T-cell responses induced by
vaccination
CD4 T-cells are depleted in HIV-1/SIV infection and
they are important in the maintenance of CD8 T-cell
effector activity (Zajac et al., 1998). In the case of SIV-
mac251 infection of macaques, virus plasma level correlates
inversely with virus-specific CD4 T-cell response, sug-
Fig. 3. Virus-specific T-cell response to Gag pool peptides and to the subdominant Gag Q19 epitope induced by vaccination. Results of animals of groups
A and B are shown. (A, left) IFN- production was measured after specific antigenic stimulation with a pool of Gag peptides in an ELISPOT assay; (right)
TNF- production was determined by intracellular cytokine staining assay following stimulation either with a pool of Gag peptides (left side) or with the
Gag Q19 peptide (right side). (B) TNF- production raw data for week 12. The percentage of CD69 TNF--secreting cells is shown at the top right in each
panel. Unstimulated control cells are shown at the left side of each group.
187A. Radaelli et al. / Virology 312 (2003) 181–195
gesting the role of CD4 T-cells in the immune control of
viremia (Hel et al., 2000). Functional analysis of SIV-
specific CD4 T-cells was therefore performed by measur-
ing both lymphocyte proliferation responses (LPRs) to SIV
antigens and intracellular cytokine staining following in
vitro stimulation with a pool of SIV Gag overlapping pep-
tides (15-mers with 11-amino-acid overlap) in macaques
from groups A and B.
Both groups of macaques exhibited proliferative re-
sponse to p27 Gag following FP-SIV-gp vaccination, and
these responses were very high [stimulation index (SI)
200] in some macaques from group A. However, the
heterogeneity in this response among macaques did not
allow for a proper statistical evaluation of a difference
between group A and group B macaques (Fig. 5A). As
expected, LPRs to gp120 were low or negative at the start of
immunization and were unaffected by vaccination (data not
shown).
An analysis of the frequency of CD4 T-helper cells
producing TNF- following Gag pool peptide stimulation
was performed in blood cells from macaques in both groups.
In all macaques from group A, discrete populations of
CD4 T-cells were still clearly detectable at 4 weeks after
immunization with FP-SIV-gp (Fig. 5, top panel). In ma-
caques from group B, Gag-specific CD4 T-cell responses
were also measured as late as 12 weeks after the first
immunization with FP-SIV-gp (week 12). Following the
second FP-SIV-gp immunization at week 13, the responses
were increased but they appeared less durable than those
induced by DNA-SIV-gp/FP-SIV-gp vaccination (Fig. 5,
lower panels) in macaques in group A. In fact, by 2 weeks
postimmunization (week 15) the extent of the responses was
equivalent to the preimmunization level in macaques from
group B. Thus, Gag-specific CD4 T-cell responses ap-
peared to be more durable in macaques immunized with
DNA prior to FP-SIV-gp vaccination.
Fig. 5. CD4 T-cell response to Gag. (A) CD4 T-cell response was determined by lymphoproliferation assay and shown for individual animals. Standard
deviation is also shown. (B) TNF- production was determined by intracellular cytokine staining assay of CD3 CD8 (CD4) T-cells after in vitro
stimulation with a pool of Gag peptides and determined for weeks 12, 14, 15, and 18 (top). Bottom panels show TNF- production raw data for week 12.
The percentage of CD69 TNF--secreting cells is shown at the top right in each panel.
Fig. 4. Virus-specific CTLs. Cytotoxic activity at a 50:1 effector:target ratio was determined at 5, 13, 15, and 17 weeks after the first immunization. PBMCs
were stimulated with IL-2 and immortalized target B-cells were pulsed either with Gag181–189 CM9 (top) or Gag Q19 peptide (bottom).
188 A. Radaelli et al. / Virology 312 (2003) 181–195
189A. Radaelli et al. / Virology 312 (2003) 181–195
Discussion
A therapeutic vaccination approach able to ameliorate
immune control of HIV-1 infection in the absence of ART
will, minimally, require the restoration of an adequate level
of virus-specific CD4 T-cell helper function in addition to
an expansion of virus-specific CD8 T-cells. The expand-
ed/induced virus-specific CD8 T-cell response should also
be of sufficient breadth to prevent immune escape during
viral rebound. At present, limited data in both humans and
macaques also support the notion that antibodies able to
neutralize the endogenous virus may be of great importance
(Montefiori et al., 2001; Tryniszewska et al., 2002). The
only live recombinant poxvirus vector-based HIV-1 vaccine
tested to date in therapeutic intervention in humans is based
on the canarypox vector. At the dose tested, the immune
response induced by ALVAC-HIV-1, albeit sizeable, was
not sufficient to confer sustained immune control of HIV-1
replication (Jin et al., 2002; Markowitz et al., 2002). Both
ALVAC-SIV-based and the highly attenuated NYVAC-
SIV-based vaccine candidates have been tested in naive
(Benson et al., 1998; Hel et al., 2002a; Pal et al., 2001;
Santra et al., 2002) and infected (Hel et al., 2000; Tryni-
szewska et al., 2002) (our unpublished results) macaques
treated with ART during primary or long-standing SIV-
mac251 infection. Whereas immune control on viral repli-
cation could not be assessed in primary infection because of
the effect of ART per se (Hel et al., 2000), in macaques with
long-standing SIVmac251 infection, both vaccines exhib-
ited an apparent equivalent immunogenicity and lowered
the set-point viremia after ART suspension (Tryniszewska
et al., 2002) (our unpublished results). However, the im-
mune control of viral replication was not durable and within
1 year plasma viral level progressively also increased in the
vaccinated macaques.
One limitation of a poxvirus-based single vaccine modality
is that the induction of immunity to the vector can interfere
with the ability to induce/expand memory response to the
desired antigen after repeated immunizations, as demonstrated
in the case of vaccinia virus (Harrington et al., 2002). There-
fore, the use of mixed modalities needs to be explored as a
means to improve both the qualitative and quantitative immune
responses induced by each independent vaccine.
Naked DNA immunization induces long-term memory re-
sponse (Gurunathan et al., 2000); however, its immunogenicity
is lower in primates than in mice. Early studies in a murine
model of malaria suggested that DNA poxvirus-based vaccine
mixed modalities were more immunogenic and afforded better
protection (Ramshaw and Ramsay, 2000; Schneider et al.,
1998; Sedegah et al., 1998). In naive macaques, the DNA
prime/live-vector boost strategy has elicited better immune
responses than DNA or poxvirus alone (Amara et al., 2001;
Hanke et al., 1999; Hel et al., 2001b; Kent et al., 1998; Lu et
al., 1996; Robinson et al., 1999). Importantly, the mixed DNA/
poxvirus vaccine modality was shown to elicit memory CD4
T-helper responses to a much higher extent than either the
poxvirus-based vaccine or DNA alone (Hel et al., 2001b).
However, whether prior DNA immunization in the context of
a therapeutic vaccination could also potentiate a poxvirus-
based vaccine was previously unknown and not necessarily
predictable.
The data presented here demonstrate that in long-term
nonprogressor SIVmac251-infected macaques the DNA/FP
vaccine modality combination is also able to induce signif-
icantly higher, broader, and more durable virus-specific
CD4 T-cell and CD8 T-cell responses than either FP or
DNA alone.
A possible explanation of this phenomenon is that DNA
immunization increases both CD4 and CD8 T-cell re-
sponses below the threshold of detection and only after
FP-SIV-gp vaccination is this subliminal expansion of an-
tigen-specific cells revealed. In the case of the second im-
munization in animals of group B, the increase of SIV-
specific immune responses would be lower than in group A
because the immune response would be partially directed to
FP proteins, as demonstrated elegantly in the murine model
using a lymphocytic choriomeningitis virus dominant
epitope in the context of a vaccinia recombinant virus (Har-
rington et al., 2002). However, the extent of this phenom-
enon may be reduced in the case of vectors that do not
replicate, as in the case of the fowlpox vector in murine
cells. In the case of DNA alone, the low immunogenicity is
probably related to the relatively inefficient expression of
DNA in tissues. Nevertheless, in the context of SIVmac
infection controlled by ART, the DNA immunization may
be exploited to circumvent the vector-directed immunity in
regimens that alternate the use of these vaccine modalities.
Orthopoxvirus and avipoxviruses all have immunostimu-
latory capacity (Fachinger et al., 2000). In particular, the
canarypox-derivative ALVAC vector has been recently
demonstrated to infect dendritic cells to induce their matu-
ration (Ignatius et al., 2000) and elicit strong HIV-1-specific
CD8 and CD4 responses in cell cultures of HIV-1-
infected peripheral blood mononuclear cells (PBMCs) (En-
gelmayer et al., 2001). Importantly, ALVAC-infected den-
dritic cells can directly stimulate and expand virus-specific
CD4 T-cells in vitro and the expansion of CD8 T-cells
is dependent on the presence of CD4 T-helper cells (En-
gelmayer et al., 2001). Fowlpox is also able to infect den-
dritic cells and stimulate antigen-specific T-cells in vitro
(Brown et al., 2000), and here we demonstrate that this
vector is able to expand both virus-specific CD4 and
CD8 T-cells in vivo. Because CD4 T-cells are the target
of HIV-1 and because of their importance in the generation
and maintenance of broad virus-specific CD8 T-cells
(Kalams et al., 1999; Matloubian et al., 1994; Zajac et al.,
1998), poxvirus-based HIV-1 vaccines may be ideal modal-
ities in combination with DNA to replenish the lost CD4
T-helper cells in HIV-1-infected individuals. A similar ap-
proach has been used in other viral infections of humans
(Chen et al., 2000) and may also be effective in cancer
immunotherapy.
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Materials and methods
Cells
Specific pathogen-free primary chick embryo fibroblasts
were maintained in Dulbecco’s minimum essential medium
supplemented with 10% heat-inactivated calf serum (Gibco,
Life Technologies, Grand Island, NY), 100 U/ml penicillin,
and 100 g/ml streptomycin. Monkey PBMCs were grown
in RPMI-1640 medium with L-glutamine (Gibco, Life Tech-
nologies) containing 10% heat-inactivated human serum
(Sigma, St. Louis, MD). Monkey B-cells were transformed
by Herpes Papio virus S594 and immortalized cells were
expanded and maintained in RPMI supplemented with 15%
heat-inactivated fetal calf serum (Gibco, Life Technologies)
and penicillin and streptomycin.
Plasmid and recombinant fowlpox virus
Plasmid pcDNA3gag/polSIV (DNA-SIV-gp), containing
the gag/pol genes of SIVmac239 and the constitutive trans-
port element of the Mason–Pfizer monkey virus, was pre-
pared as already described (Radaelli et al., 2002) and am-
plified using the endofree DNA extraction kit (Qiagen,
Valencia, CA). Viral stocks were prepared on primary chick
embryo fibroblasts, purified on a sucrose gradient, titered,
and used for animal immunization. The correct expression
of both the gag/pol genes of pcDNA3-SIVgag/pol (Radaelli
et al., 2002) as well as of the FP-SIV-gp (FP74) recombi-
nant were previously demonstrated (Jenkins et al., 1991).
Animals
Eight colony-bred rhesus macaques (Macaca mulatta),
obtained from Covance Research Products (Alice, TX),
were infected with the same strain of SIVmac251 (561) (Pal
et al., 2001) and treated daily with a combination of potent
antiviral drugs: 20 mg/kg/day sc of (R)-9-2-phosphonyl-
methoypropyladenine (PMPA) (started at day 15) and 5
mg/kg/day ip of didanosine (DDI; Videx, Bristol-Meyers
Squibb, Princeton, NJ). The treatment was continued for 6
months and the macaques were vaccinated with NYVAC-
SIV-gpe or NYVAC alone during ART (Hel et al., 2000)
(for details, see Table 1). Once therapy was suspended, viral
rebound occurred in most animals but was subsequently
contained as a result of early ART intervention (Franchini,
2002). ART was initiated again for the purpose of this study
1 month before the first immunization and maintained dur-
ing the entire immunization regimen to minimize fluctuation
in viral replication that may have influenced the response to
vaccination. All macaques were Mamu-A*01-positive as
demonstrated by reverse transcription–polymerase chain re-
action (Kuroda et al., 1998) and were housed and handled in
accordance with the standards of the American Association
for the Accreditation of Laboratory Animal Care.
Immunization protocols
Eight rhesus monkeys were divided into two groups of
four animals each. Animals of group A (636, 649, 680, and
682) were immunized with 4 mg/animal of DNA-SIV-gp (3
mg im and 1 mg id) and boosted after 8 weeks with a single
inoculation of 2  108 pfu/animal intramuscularly of FP-
SIV-gp. Animals in group B (645, 650, 681, and 706) were
immunized at first intramuscularly with 2  108 PFU/
animal FP-SIV-gp and boosted after 13 weeks with the
same dose of the same vaccine. Blood was collected weekly
and PBMCs were isolated by Ficoll. Serum fraction aliquots
were also collected and frozen at 80°C until used.
NASBA and CD4 and CD8 T-cell counts
RNA detection was performed by the nucleic acid se-
quence-based amplification (NASBA) technology. Briefly,
RNA was extracted from plasma and isothermally amplified
using SIVmac251-specific primers. Quantification was
made by electrochemiluminescence-chemistry-based probe
hybridization system using a coextracted internal standard.
The copy number is expressed per hundred microliters of
plasma, the detection limit of the assay being 2  103 RNA
copies.
CD4 and CD8 counts were periodically determined
on 100 l of whole blood and by FACS analysis, according
to the FACS/Lyse kit (BD Immunocytometry Systems, San
Jose, CA) with minor modifications. Briefly, after incubat-
ing 10 l of a mixture containing PerCP-CD4, APC-CD8,
PE-CD45, and FITC-CD3 Ab (BD Immunocytometry Sys-
tems) for 30 min at room temperature, red cells were lysed
by adding 2 ml of FACS/Lyse solution for 15 min. Samples
were then centrifuged for 5 min at 1200 rpm at room
temperature, washed [1% fetal calf serum (FCS) and 0.05%
NaAzide in phosphate-buffered saline (PBS)], resuspended
in 500 l wash buffer, and stored at 4°C until acquired by
a FACSCalibur flow cytometer (Becton–Dickinson). The
counts were expressed as a percentage of CD3/CD4 or
CD3/CD8 lymphocytes/l.
Tetramer staining
The Mamu-A*01 tetrameric complex, refolded in the
presence of the Gag181–189 CM9 peptide, was kindly sup-
plied by J.D. Altman (Emory University Vaccine Center at
Yerkes, Atlanta, Georgia) and conjugated to streptavidin
(Molecular Probes, Eugene, OR). Fresh PBMCs (5  103)
per animal were simultaneously stained with differently
conjugated antihuman Abs: PerCP-CD8 (BD Immunocy-
tometry Systems), FITC-CD3 (BD PharMingen, San Di-
ego, CA), and the PE-conjugated tetrameric complex. PE-
CD4 (BD PharMingen) Ab was used for the positive
control. After 30 min of incubation in the dark at room
temperature, cells were washed with 2% FCS in PBS and
fixed with 1% paraformaldehyde in PBS (pH 7.4). Samples
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were analyzed on a FACSCalibur flow cytometer (Becton–
Dickinson) and cells were sorted and expressed as a per-
centage of tetramer-positive cells over the total CD8 T-
lymphocyte population.
ELISPOT assay
ELISPOT assay was performed with the monkey-spe-
cific IFN- U-Cytech kit (Utrecht, The Netherlands), fol-
lowing the manufacturer’s specifications. Briefly, after coat-
ing with anti-IFN- mAb, plates were incubated overnight
at 4°C and washed and aspecific sites covered with 2%
bovine serum albumin in PBS at 4°C for 3 to 5 h. PBMCs
(105) were plated per each well in RPMI-1640 containing
5% heat-inactivated human serum and stimulated in tripli-
cate with Gag181–189 CM9, Gag Q19, or a pool of Gag or
Env peptides, each at 1 g/ml. Concanavalin A (5 g/ml)
was used as a positive control. After overnight incubation at
37°C in a 5% CO2 atmosphere, plates were developed and
SFCs counted onto a Leitz Diavert inverted microscope.
Intracellular cytokine staining
Intracellular cytokine staining was performed using the
anti-TNF- antibody. Fresh PBMCs (106) in 1 ml complete
medium were incubated for 1 h at 37°C in the absence or
presence of Gag181–189 CM9 (10 g/ml), Gag Q19 (10
g/ml), or a pool of Gag peptides (2 g/ml) and in the
presence of CD28 and CD49d (1 g/ml each). After addi-
tion of 10 g/ml Brefeldin A (Sigma), cells were incubated
for 5 h at 37°C and processed for surface and intracellular
cytokine staining. Briefly, after treatment with 2 mM EDTA
and incubation at room temperature for 15 min, cells were
washed twice with 1% FCS in PBS, surface-stained with
FITC-CD3 and PerCP-CD8 (10 l each), washed again,
and permeabilized with FACSPerm (BD PharMingen) for
10 min at room temperature in the dark. Following two
further washes, cells were intracellular-stained with PE-
CD69 (0.006 g) and allophycocyanin-conjugated-TNF-
(0.4 g, BD PharMingen), incubated for 25 min at 37°C,
fixed with 500 l 1% paraformaldehyde (Sigma) in PBS,
and analyzed by four-color flow cytometry (Becton–Dick-
inson).
CTL assay
Monkey PBMCs were stimulated overnight with 100 U
IL-2 (Roche, Indianapolis, IN) in 1 ml complete medium,
washed in HBSS, and plated in triplicate on a 96-well
round-bottomed plate. Mamu-A*01-positive Herpes Papio-
transformed target cells were stimulated overnight with 10
g Gag181–189 CM9 or Gag Q19 peptides in 1 ml complete
medium, labeled for 2 h with 100 Ci 51Cr, and washed in
HBSS, and 5 103 cells were added to each well. Unstimu-
lated target cells were used as a negative control. Cells were
incubated for 6 h at effector-to-target-cell ratios of 50:1,
25:1, 12.5:1, and 6.25:1 and the percentage of released 51Cr
was calculated by dividing the difference between the mean
counts per minute of experimental and spontaneous release
by the difference between the mean counts per minute of
total and spontaneous release.
Lymphocyte proliferation assay
Monkey PBMCs, isolated by lymphocyte separation me-
dium (Cappel, ICN Biomedicals Inc., Aurora, OH) from
EDTA or heparinized blood, were prepared according to the
manufacturer’s specifications and plated at 3  105/well
into flat-bottomed 96-well plates. Cells were stimulated
with 1 g/well of p27 (Advanced BioScience Laboratories,
Rockville, MD), 1 g/well of gp120 (Advanced BioScience
Laboratories), or 5 g/well of concanavalin A (Sigma) as a
positive control. On day 3, 1 C [methyl-3H]thymidine
(NEN, Life Science Products, Boston, MA) was added to
each microculture. Following an 18-h incubation, cells were
harvested with a Tomtec cell harvester (Model No. 96,
CraMar Technologies, Westminster, CO) and the incorpo-
rated radioactivity was determined in a Wallac 1205 Beta-
plate liquid scintillation counter (Amersham Pharmacia
Biotech, Piscataway, NJ). The SI was calculated by dividing
the mean counts per minute of [methyl-3H]thymidine incor-
porated into antigen-pulsed cells by the mean counts incor-
porated into unstimulated cells. Experiments were per-
formed in triplicate for each animal.
Statistical analyses
The percentage of tetramer-positive CD8 lymphocytes
was analyzed by repeated measures analysis of variance
applied to the arc-sine-transformed data. All P values were
two-tailed. The Number Cruncher Statistical System
(NCSS, Kaysville, UT), Sigmastat (version 2.0; SPSS, Chi-
cago, IL), and the SAS System for Windows (release 8.00;
SAS Institute Inc., Cary, NC) statistical software packages
were used for the analyses.
Acknowledgments
We thank John D. Altman for the tetramers, Norbert
Bischofberger for PMPA, and Steven Snodgrass for edito-
rial assistance. This project was supported in part by the
Italian Ministry of Health (National Program of AIDS,
Grant Numbers 40B.34 and 40C.31 and the Italy–USA
Program for the Development of HIV/AIDS Vaccines, Con-
certed Action number 45D/1.20) and by MURST (COFIN
1999 and 2001). Dr. Radaelli was a recipient of a fellowship
from the rector of the University of Milan.
192 A. Radaelli et al. / Virology 312 (2003) 181–195
References
Amara, R.R., Villinger, F., Altman, J.D., Lydy, S.L., O’Neil, S.P., Stap-
rans, S.I., Montefiori, D.C., Xu, Y., Hemdon, J.G., Wyatt, L.S., Can-
dido, M.A., Kozyr, N.L., Earl, P.L., Smith, J.M., Ma, H.L., Grimm,
B.D., Hulsey, M.L., Miller, J., McClure, H.M., McNicholl, J.M., Moss,
B., Robinson, H.L., 2001. Control of a mucosal challenge and preven-
tion of AIDS by a multiprotein DNA/MVA vaccine. Science 292,
69–74.
Appay, V., Nixon, D.F., Donahoe, S.M., Gillespie, G.M.A., Dong, T.,
King, A., Ogg, G.S., Spiegel, H.M.L., Conlon, C., Spina, C.A., Havlir,
D.V., Richman, D.D., Waters, A., Easterbrook, P., McMichael, A.J.,
Rowland-Jones, S.L., 2000. HIV-specific CD8 T cells produce anti-
viral cytokines but are impaired in cytolytic function. J. Exp. Med. 192,
63–75.
Autran, B., Carcelain, G., Li, T.S., Blanc, C., Mathez, D., Tubiana, R.,
Katlama, C., Debre, P., Leibowitch, J., 1997. Positive effects of com-
bined antiretroviral therapy on CD4 T cell homeostasis and function
in advanced HIV disease. Science 277, 112–116.
Benson, J., Chougnet, C., Robert-Guroff, M., Montefiori, D., Markham,
P.D., Shearer, G.M., Gallo, R.C., Cranage, M.P., Paoletti, E., Limbach,
K., Venzon, D., Tartaglia, J., Franchini, G., 1998. Recombinant vac-
cine-induced protection against the highly pathogenic SIVmac251: de-
pendence on route of challenge exposure. J. Virol. 72, 4170–4182.
Brown, M., Zhang, Y., Dermine, S., de Wynter, E.A., Hart, C., Kitchener,
H., Stern, P.L., Skinner, M.A., Stacey, S.N., 2000. Dendritic cells
infected with recombinant fowlpox virus vectors are potent and long-
acting stimulators of transgene-specific class I restricted T lymphocyte
activity. Gene Ther. 7, 1680–1689.
Chen, C.H., Wang, T.L., Hung, C.F., Pardoll, D.M., Wu, T.C., 2000.
Boosting with recombinant vaccinia increases HPV-16 E7-specific T
cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Vaccine 18, 2015–2022.
Davey Jr., R.T., Bhat, N., Yoder, C., Chun, T.W., Metcalf, J.A., Dewar, R.,
Natarajan, V., Lempicki, R.A., Adelsberger, J.W., Miller, K.D., Ko-
vacs, J.A., Polis, M.A., Walker, R.E., Falloon, J., Masur, H., Gee, D.,
Baseler, M., Dimitrov, D.S., Fauci, A.S., Lane, H.C., 1999. HIV-1 and
T cell dynamics after interruption of highly active antiretroviral therapy
(HAART) in patients with a history of sustained viral suppression.
Proc. Natl. Acad. Sci. USA 96, 15109–15114.
Engelmayer, J., Larsson, M., Lee, A., Lee, M., Cox, W.I., Steinman, R.M.,
Bhardwaj, N., 2001. Mature dendritic cells infected with canarypox
virus elicit strong anti-human immunodeficiency virus CD8 and
CD4 T-cell responses from chronically infected individuals. J. Virol.
75, 2142–2153.
Fachinger, V., Schlapp, T., Strube, W., Schmeer, N., Saalmuller, A., 2000.
Poxvirus-induced immunostimulating effects on porcine leukocytes.
J. Virol. 74, 7943–7951.
Franchini, G., 2002. Modeling immune intervention strategies for HIV-1
infection of humans in the macaque model. Clin. Appl. Immunol. Rev.,
in press.
Goepfert, P.A., Bansal, A., Edwards, B.H., Ritter, G.D., Tellez, I., McPher-
son, S.A., Sabbaj, S., Mulligan, M.J., 2000. A significant number of
human immunodeficiency virus epitope-specific cytotoxic T lympho-
cytes detected by tetramer binding do not produce gamma interferon.
J. Virol. 74, 10249–10255.
Gray, C.M., Lawrence, J., Schapiro, J.M., Altman, J.D., Winters, M.A.,
Crompton, M., Loi, M., Kundu, S.K., Davis, M.M., Merigan, T.C.,
1999. Frequency of class I HLA-restricted anti-HIV CD8 T cells in
individuals receiving highly active antiretroviral therapy (HAART).
J. Immunol. 162, 1780–1788.
Gurunathan, S., Wu, C.Y., Freidag, B.L., Seder, R.A., 2000. DNA vac-
cines: a key for inducing long-term cellular immunity. Curr. Opin.
Immunol. 12, 442–447.
Hanke, T., Samuel, R.V., Blanchard, T.J., Neumann, V.C., Allen, T.M.,
Boyson, J.E., Sharpe, S.A., Cook, N., Smith, G.L., Watkins, D.I.,
Cranage, M.P., McMichael, A.J., 1999. Effective induction of simian
immunodeficiency virus-specific cytotoxic T lymphocytes in macaques
by using a multiepitope gene and DNA prime-modified vaccinia virus
ankara boost vaccination regimen. J. Virol. 73, 7524–7532.
Harrington, L.E., Most, R.R., Whitton, J.L., Ahmed, R., 2002. Recombi-
nant vaccinia virus-induced T-cell immunity: quantitation of the re-
sponse to the virus vector and the foreign epitope. J. Virol. 76, 3329–
3337.
Hel, Z., Nacsa, J., Kelsall, B., Tsai, W.P., Letvin, N., Parks, R.W.,
Tryniszewska, E., Picker, L., Lewis, M.G., Edghill-Smith, Y., Mo-
niuszko, M., Pal, R., Stevceva, L., Altman, J.D., Allen, T.M., Watkins,
D., Torres, J.V., Berzofsky, J.A., Belyakov, I.M., Strober, W.,
Franchini, G., 2001a. Impairment of Gag-specific CD8() T-cell func-
tion in mucosal and systemic compartments of simian immunodefi-
ciency virus mac251- and simian-human immunodeficiency virus
KU2-infected macaques. J. Virol. 75, 11483–11495.
Hel, Z., Nacsa, J., Tryniszewska, E., Tsai, W.P., Parks, R.W., Montefiori,
D.C., Felber, B.K., Tartaglia, J., Pavlakis, G.N., Franchini, G., 2002a.
Containment of simian immunodeficiency virus infection in vaccinated
macaques: correlation with the magnitude of virus-specific pre- and
postchallenge CD4() and CD8() T cell responses. J. Immunol. 169,
4778–4787.
Hel, Z., Nacsa, J., Tsai, W.P., Thornton, A., Giuliani, L., Tartaglia, J.,
Franchini, G., 2002b. Equivalent immunogenicity of the highly atten-
uated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candi-
dates in SIVmac251-infected macaques. Virology, 304, 125–134.
Hel, Z., Tsai, W.P., Thornton, A., Nacsa, J., Giuliani, L., Tryniszewska, E.,
Poudyal, M., Venzon, D., Wang, X., Altman, J., Watkins, D.I., Lu, W.,
von Gegerfelt, A., Felber, B.K., Tartaglia, J., Pavlakis, G.N., Franchini,
G., 2001b. Potentiation of simian immunodeficiency virus (SIV)-spe-
cific CD4() and CD8() T cell responses by a DNA-SIV and NY-
VAC-SIV prime/boost regimen. J. Immunol. 167, 7180–7191.
Hel, Z., Venzon, D., Poudyal, M., Tsai, W.-P., Giuliani, L., Woodward, R.,
Chougnet, C., Shearer, G.M., Altman, J.D., Watkins, D.I., Bischof-
berger, N., Abimiku, A.G., Markham, P.D., Tartaglia, J., Franchini, G.,
2000. Viremia control following antiretroviral treatment and therapeu-
tic immunization during primary SIV251 infection of macaques. Nat.
Med. 6, 1140–1146.
Ignatius, R., Marovich, M., Mehlhop, E., Villamide, L., Mahnke, K., Cox,
W.I., Isdell, F., Frankel, S.S., Mascola, J.R., Steinman, R.M., Pope, M.,
2000. Canarypox virus-induced maturation of dendritic cells is medi-
ated by apoptotic cell death and tumor necrosis factor alpha secretion.
J.Virol. 74, 11329–11338.
Jenkins, S., Gritz, L., Fedor, C.H., O’Neill, E.M., Cohen, L.K., Panicali,
D.L., 1991. Formation of lentivirus particles by mammalian cells in-
fected with recombinant fowlpox virus. AIDS Res. Hum. Retroviruses
7, 991–998.
Jin, X., Bauer, D.E., Tuttleton, S.E., Lewin, S., Gettie, A., Blanchard, J.,
Irwin, C.E., Safrit, J.T., Mittler, J., Weinberger, L., Kostrikis, L.G.,
Zhang, L., Perelson, A.S., Ho, D.D., 1999. Dramatic rise in plasma
viremia after CD8 T cell depletion in simian immunodeficiency
virus-infected macaques. J. Exp. Med. 189, 991–998.
Jin, X., Ramanathan Jr., M., Barsoum, S., Deschenes, G.R., Ba, L., Binley,
J., Schiller, D., Bauer, D.E., Chen, D.C., Hurley, A., Gebuhrer, L., El
Habib, R., Caudrelier, P., Klein, M., Zhang, L., Ho, D.D., Markowitz,
M., 2002. Safety and immunogenicity of ALVAC vCP1452 and re-
combinant gp160 in newly human immunodeficiency virus type 1-in-
fected patients treated with prolonged highly active antiretroviral ther-
apy. J. Virol. 76, 2206–2216.
Kalams, S.A., Buchbinder, S.P., Rosenberg, E.S., Billingsley, J.M., Col-
bert, D.S., Jones, N.G., Shea, A.K., Trocha, A.K., Walker, B.D., 1999.
Association between virus-specific cytotoxic T-lymphocyte and helper
responses in human immunodeficiency virus type 1 infection. J. Virol.
73, 6715–6720.
Kent, S.J., Zhao, A., Best, S.J., Chandler, J.D., Boyle, D.B., Ramshaw,
I.A., 1998. Enhanced T-cell immunogenicity and protective efficacy of
a human immunodeficiency virus type 1 vaccine regimen consisting of
193A. Radaelli et al. / Virology 312 (2003) 181–195
consecutive priming with DNA and boosting with recombinant fowl-
pox virus. J. Virol. 72, 10180–10188.
Koup, R.A., Safrit, J.T., Cao, Y., Andrew, C.A., McLeod, G., Borkowsky,
W., Farthing, C., Ho, D.D., 1994. Temporal association of cellular
immune responses with the initial control of viremia in primary human
immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655.
Kuroda, M.J., Schmitz, J.E., Barouch, D.H., Craiu, A., Allen, T.M., Sette,
A., Watkins, D.I., Forman, M.A., Letvin, N.L., 1998. Analysis of
Gag-specific cytotoxic T lymphocytes in simian immunodeficiency
virus-infected rhesus monkeys by cell staining with a tetrameric major
histocompatibility complex class I-peptide complex. J. Exp. Med. 187,
1373–1381.
Lifson, J.D., Rossio, J.L., Arnaout, R., Li, L., Parks, T.L., Schneider, D.K.,
Kiser, R.F., Coalter, V.J., Walsh, G., Imming, R.J., Fisher, B., Flynn,
B.M., Bischofberger, N., Piatak, M.J., Hirsch, V.M., Nowak, M.A.,
Wodarz, D., 2000. Containment of simian immunodeficiency virus
infection: cellular immune responses and protection from rechallenge
following transient postinoculation antiretroviral treatment. J. Virol.
74, 2584–2593.
Lori, F., Lewis, M.G., Xu, J., Varga, G., Zinn, D.E.J., Crabbs, C., Wagner,
W., Greenhouse, J., Silvera, P., Yalley-Ogunro, J., Tinelli, C., Lis-
ziewicz, J., 2000. Control of SIV rebound through structured treatment
interruptions during early infection. Science 290, 1591–1593.
Lori, F., Lisziewicz, J., 2001. Structured treatment interruptions for the
management of HIV infection. J. Am. Med. Assoc. 286, 2981–2987.
Lu, S., Arthos, J., Montefiori, D.C., Yasutomi, Y., Manson, K., Mustafa, F.,
Johnson, E., Santoro, J.C., Wissink, J., Mullins, J.I., Haynes, J.R.,
Letvin, N.L., Wyand, M., Robinson, H.L., 1996. Simian immunodefi-
ciency virus DNA vaccine trial in macaques. J. Virol. 70, 3978–3991.
Markowitz, M., Jin, X., Hurley, A., Simon, V., Ramratnam, B., Louie, M.,
Deschenes, G.R., Ramanathan Jr., M., Barsoum, S., VanderHoeven, J.,
He, T., Chung, C., Murray, J., Perelson, A.S., Zhang, L., Ho, D.D.,
2002. Discontinuation of antiretroviral therapy commenced early dur-
ing the course of human immunodeficiency virus type 1 infection, with
or without adjunctive vaccination. J. Infect. Dis. 186, 634–643.
Markowitz, M., Vesanen, M., Tenner-Racz, K., Cao, Y., Binley, J.M.,
Talal, A., Hurley, A., Jin, X., Chaudhry, M.R., Yaman, M., Frankel, S.,
Health-Chiozzi, M., Leonard, J.M., Moore, J.P., Racz, P., Nixon, D.F.,
Ho, D.D., 1999. The effect of commencing combination antiretroviral
therapy soon after human immunodeficiency virus type 1 infection on
viral replication and antiviral immune responses. J. Infect. Dis. 179,
527–537.
Matano, T., Shibata, R., Siemon, C., Connors, M., Lane, H., Martin, M.A.,
1998. Administration of an anti-CD8 monoclonal antibody interferes
with the clearance of chimeric simian/human immunodeficiency virus
during primary infections of rhesus macaques. J. Virol. 72, 164–169.
Matloubian, M., Concepcion, R.J., Ahmed, R., 1994. CD4 T cells are
required to sustain CD8 cytotoxic T-cell responses during chronic
viral infection. J. Virol. 68, 8056–8065.
Montefiori, D.C., Hill, T.S., Vo, H.T., Walker, B.D., Rosenberg, E.S.,
2001. Neutralizing antibodies associated with viremia control in a
subset of individuals after treatment of acute human immunodeficiency
virus type 1 infection. J. Virol. 75, 10200–10207.
Mori, K., Yasutomi, Y., Sawada, S., Villinger, F., Sugama, K., Rosenwith,
B., Heeney, J.L., Uberla, K., Yamazaki, S., Ansari, A.A., Rubsamen-
Waigmann, H., 2000. Suppression of acute viremia by short-term
postexposure prophylaxis of simian/human immunodeficiency virus
SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor
(GW420867) allows for development of potent antiviral immune re-
sponses resulting in efficient containment of infection. J. Virol. 74,
5747–5753.
Musey, L.K., Krieger, J.N., Hughes, J.P., Schacker, T.W., Corey, L.,
McElrath, M.J., 1999. Early and persistent human immunodefi-
ciency virus type 1 (HIV-1)-specific T helper dysfunction in blood
and lymph nodes following acute HIV-1 infection. J. Infect. Dis.
180, 278 –284.
Ogg, G.S., Jin, X., Bonhoeffer, S., Moss, P., Nowak, M.A., Monard, S.,
Segal, J.P., Cao, Y., Rowland-Jones, S.L., Hurley, A., Markowitz,
M., Ho, D.D., McMichael, A.J., Nixon, D.F., 1999. Decay kinetics
of human immunodeficiency virus-specific effector cytotoxic T lym-
phocytes after combination antiretroviral therapy. J. Virol. 73, 797–
800.
Ortiz, G.M., Nixon, D.F., Trkola, A., Binley, J., Jin, X., Bonhoeffer, S.,
Kuebler, P.J., Donahoe, S.M., Demoitie, M.A., Kakimoto, W.M., Ke-
tas, T., Clas, B., Heymann, J.J., Zhang, L., Cao, Y., Hurley, A., Moore,
J.P., Ho, D.D., Markowitz, M., 1999. HIV-1-specific immune re-
sponses in subjects who temporarily contain virus replication after
discontinuation of highly active antiretroviral therapy. J. Clin. Invest.
104, R13–R18.
Pal, R., Venzon, D., Letvin, N.L., Santra, S., Montefiori, D.C., Miller,
N.R., Tryniszewska, E., Lewis, M.G., Vancott, T.C., Hirsch, V., Wood-
ward, R., Gibson, A., Grace, M., Dobratz, E., Markham, P.D., Hel, Z.,
Nacsa, J., Klein, M., Tartaglia, J., Franchini, G., 2001. ALVAC-SIV-
gag-pol-env-based vaccination and macaque major histocompatibility
complex class I (A*01) delay simian immunodeficiency virus SIV-
(mac)-induced immunodeficiency. J. Virol. 76, 292–302.
Palella Jr., F.J., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer,
J., Satten, G.A., Aschman, D.J., Holmberg, S.D., 1998. Declining
morbidity and mortality among patients with advanced human immu-
nodeficiency virus infection: HIV Outpatient Study Investigators.
N. Engl. J. Med. 338, 853–860.
Pitcher, C.J., Quittner, C., Peterson, D.M., Connors, M., Koup, R.A.,
Maino, V.C., Picker, L.J., 1999. HIV-1-specific CD4 T cells are
detectable in most individuals with active HIV-1 infection, but decline
with prolonged viral suppression. Nat. Med. 5, 518–525.
Radaelli, A., Zanotto, C., Perletti, G., Elli, V., Vicenzi, E., Poli, G., De
Giuli Morghen, C., 2002. Comparative analysis of immune responses
and cytokine profiles elicited by rabbits in the combined use of fowlpox
viruses, plasmids, and virus-like particles in prime-boost vaccination
protocols against SHIV. Vaccine, in press.
Ramshaw, I.A., Ramsay, A.J., 2000. The prime-boost strategy: exciting
prospects for improved vaccination. Immunol. Today 21, 163–165.
Robinson, H.L., Montefiori, D., Johnson, R.P., Manson, K.H., Kalish,
M.L., Lifson, J.D., Rizvi, T.A., Lu, S., Hu, S.-L., Mazzara, G.P.,
Panicali, D.L., Herndon, J.G., Glickman, R., Candido, M.A., Lydy,
S.L., Wyand, M.S., McClure, H.M., 1999. Neutralizing antibody-inde-
pendent containment of immunodeficiency virus challenges by DNA
priming and recombinant pox virus booster immunizations. Nat. Med.
5, 526–534.
Rosenberg, E.S., Altfeld, M., Poon, S.H., Phillips, M.N., Wilkes, B.M.,
Eldridge, R.L., Robbins, G.K., D’Aquila, R.T., Goulder, P.J., Walker,
B.D., 2000. Immune control of HIV-1 after early treatment of acute
infection. Nature 407, 523–526.
Rosenberg, E.S., Billingsley, J.M., Caliendo, A.M., Boswell, S.L., Sax,
P.E., Kalams, S.A., Walker, B.D., 1997. Vigorous IIIV-1-specific
CD4 T-cell responses associated with control of viremia. Science
278, 1447–1450.
Santra, S., Schmitz, J.E., Kuroda, M.J., Lifton, M.A., Nickerson, C.E.,
Lord, C.I., Pal, R., Franchini, G., Letvin, N.L., 2002. Recombinant
canarypox vaccine-elicited CTL specific for dominant and subdomi-
nant simian immunodeficiency virus epitopes in rhesus monkeys. J. Im-
munol. 168, 1847–1853.
Schmitz, J.E., Kuroda, M.J., Veazey, R.S., Seth, A., Taylor, W.M., Nick-
erson, C.E., Lifton, M.A., Dailey, P.J., Forman, M.A., Racz, P., Ten-
ner-Racz, K., Letvin, N.L., 2000. Simian immunodeficiency virus
(SIV)-specific CTL are present in large numbers in livers of SIV-
infected rhesus monkeys. J. Immunol. 164, 6015–6019.
Schneider, J., Gilbert, S.C., Blanchard, T.J., Hanke, T., Robson, K.J.,
Hannan, C.M., Becker, M., Sinden, R., Smith, G.L., Hill, A.V., 1998.
Enhanced immunogenicity for CD8 T cell induction and complete
protective efficacy of malaria DNA vaccination by boosting with mod-
ified vaccinia virus Ankara. Nat. Med. 4, 397–402.
194 A. Radaelli et al. / Virology 312 (2003) 181–195
Sedegah, M., Jones, T.R., Kaur, M., Hedstrom, R., Hobart, P., Tine, J.A.,
Hoffman, S.L., 1998. Boosting with recombinant vaccinia increases
immunogenicity and protective efficacy of malaria DNA vaccine. Proc.
Natl. Acad. Sci. USA 95, 7648–7653.
Shankar, P., Russo, M., Harnisch, B., Patterson, M., Skolnik, P., Lieberman, J.,
2000. Impaired function of circulating HIV-specific CD8() T cells in
chronic human immunodeficiency virus infection. Blood 96, 3094–3101.
Tryniszewska, E., Nacsa, J., Lewis, M.G., Silvera, P., Montefiori, D.,
Venzon, D., Hel, Z., Parks, R.W., Moniuszko, M., Tartaglia, J., Smith,
K.A., Franchini, G., 2002. Vaccination of macaques with long-standing
SIVmac251 infection lowers the viral set point after cessation of
antiretroviral therapy. J. Immunol. 169, 5347–5357.
Tsai, C.-C., Follis, K.E., Beck, T.W., Sabo, A., Grant, R.F., Bischofberger,
N., 1995. Prevention of simian immunodeficiency virus infection in
macaques by 9-(2-phosphonylmethoxypropyl) adenine (PMPA). Sci-
ence 270, 1197–1199.
Villinger, F., Brice, G.T., Mayne, A.E., Bostik, P., Mori, K., June, C.H.,
Ansari, A.A., 2002. Adoptive transfer of simian immunodeficiency
virus (SIV) naive autologous CD4() cells to macaques chronically
infected with SIV is sufficient to induce long-term nonprogressor
status. Blood 99, 590–599.
Vogel, T.U., Allen, T.M., Altman, J.D., Watkins, D.I., 2001. Functional
impairment of simian immunodeficiency virus-specific CD8 T cells
during the chronic phase of infection. J. Virol 75, 2458–2461.
Zajac, A.J., Blattman, J.N., Murali-Krishna, K., Sourdive, D.J.D., Suresh,
M., Altman, J.D., Ahmed, R., 1998. Viral immune evasion due to
persistence of activated T cells without effector function. J. Exp. Med.
188, 2205–2213.
195A. Radaelli et al. / Virology 312 (2003) 181–195
